Dianthus Therapeutics, Inc.
DNTH
$43.97
$1.694.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 105.18% | -83.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 105.18% | -83.40% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 105.18% | -83.40% | |||
| SG&A Expenses | -7.60% | 20.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.84% | 2.27% | |||
| Operating Income | -15.35% | -5.27% | |||
| Income Before Tax | -16.24% | -7.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.24% | -7.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.24% | -7.18% | |||
| EBIT | -15.35% | -5.27% | |||
| EBITDA | -15.37% | -5.27% | |||
| EPS Basic | -10.18% | -7.08% | |||
| Normalized Basic EPS | -13.72% | -4.23% | |||
| EPS Diluted | -10.18% | -7.08% | |||
| Normalized Diluted EPS | -13.72% | -4.23% | |||
| Average Basic Shares Outstanding | 5.50% | 0.09% | |||
| Average Diluted Shares Outstanding | 5.50% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||